Please login to the form below
lymphoma
This page shows the latest lymphoma news and features for those working in and with pharma, biotech and healthcare.
Roche’s Polivy recommended by NICE for lymphoma therapy
In final draft guidance, NICE recommended the antibody drug conjugate be used in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) for untreated diffuse large B-cell lymphoma (DLBCL).
Latest news
-
Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
Gilead Science and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) to treat certain forms of lymphoma. ... Specifically, the therapy is now
-
BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), the company announced. ... lymphoma (MZL) who have received
-
Biogen and Genentech sign royalty agreement for blood cancer drug glofitamab
Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody currently under development for the treatment of B-cell non-Hodgkin’s lymphomas, including diffuse large B-cell lymphoma (DLBCL), mantle ... it the first and only
-
Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma
and prednisone (R-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL). ... This was evaluated by the investigator using the Lugano Response Criteria for malignant lymphoma.
-
Janssen’s Imbruvica shows promise in chronic lymphocytic leukaemia study
Ryan Jacobs, principal study investigator, clinical director, division of lymphoma therapy and research, department of haematologic oncology, Atrium Health Levine Cancer Institute.
More from news
Approximately 75 fully matching, plus 412 partially matching documents found.
Latest Intelligence
-
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
In mantle cell lymphoma – where patients often require unpleasant stem cell transplantation procedures – TKI growth-blocker technology is increasing failure-free survival rates in younger patients.
-
ASH 2022: bad blood but big advances
Special interest sessions during the ASH-FDA Joint Symposium picked out advances in disease states as diverse as multiple myeloma, B-cell lymphoma and AML, while in non-malignant haematology it ... One of the most groundbreaking announcements came in
-
CAR-T cell therapy in oncology
large B-cell lymphoma, acute lymphoblastic leukaemia and other relapsed/ refractory haematologic cancer. ... tumour antigens, such as CD-19, CD20 and CD22, found predominantly in leukaemia and lymphoma.
-
Growing evidence supports the important role of biosimilars in healthcare
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
-
Surviving cancer: a new era for patients
CAR-T therapy has potential across all tumour types, with recent results showing impressive overall response rates and complete response rates in patients with aggressive B-cell lymphomas.
More from intelligence
Approximately 0 fully matching, plus 36 partially matching documents found.
Latest appointments
-
New hires at Abbott, Kite and Arrakis Therapeutics
Previously, he spent many years at Celgene, where he was corporate vice president for clinical R7D and the therapeutic area head for Lymphoma and CLL.
-
Kite Pharma appoints cancer immunotherapy experts
Dr Ronald Levy (pictured) is director of the lymphoma programme at Stanford University, Dr Zelig Eshhar is chairman of immunology research at the Tel Aviv Sourasky Medical Center, and Dr Inder
-
Charles Morris appointed chief development officer at ImmunoGen
cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.
-
Sutro Biopharma hires chief business officer and VP research
During his time at Allos, he set up a collaboration with Mundipharma for the co-development and commercialisation of lymphoma therapy Folotyn (pralatrexate) outside the US and Canada.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
The dissemination and consumption of medical literature is evolving
We’ve done this for 8 conferences this year, events like the Neurology Exchange, The Annual T-Cell Lymphoma Forum, Psychiatry Winter Update and we will be doing even more in
-
Medscape Education Global
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide.
-
Highlights in haematologic malignancy from ASH 2018
refractory diffuse large B-cell lymphoma.
-
Australian Flu and the dilemma of naming diseases
s Lymphoma and Parkinsons.
-
Attracting doctors to low-demand specialties: A role for industry?
such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two sessions.
More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- GSK to submit drug application for new antibiotic to US FDA
- EU outlines measures to mitigate antibiotic shortage across Europe
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
